1月26日，南微医学跌5.04%，截至发稿，报81.18元/股，成交1.12亿元，换手率0.72%，总市值152.49亿 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模252.63亿。今年以来收益9.07%，同类 排名2041/5579；近一年收益19.46%，同类排名3487/4270；成立以来收益11.04%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年106天，现任基金资产总规模1013.58亿元，任职期间最佳基金回报 163.58%， 任职期间最差基金回报-98.01%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 资料显示，南微医学科技股份有限公司位于 ...

华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年101天，现任基金资产总规模1002.04亿元，任职期间最佳基金回报 165.65%， 任职期间最差基金回报-98.01%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 1月21日，通策医疗涨5.19%，截至发稿，报46.60元/股，成交5.70亿元，换手率2.80%，总市值208.44亿 元。 资料显示，通策医疗股份有限公司位于杭州市西湖区西溪路双口井巷1号通策医疗大厦，成立日期1995 年8月30日，上市日期1996年10月30日，公司主营业务涉及医疗服务投资及口腔医疗服务。主营业务收 入构成为：医疗服务92.84%，产品销售4.06%，建筑工程2.72%，其他0.38%。 从通策医疗十大流通股东角度 数据显示，华宝基金旗下1只基金位居通策医疗十大流通股东。华宝中证医疗ETF（512170）三季度减 持158.04万股，持有股数888.54万股，占流通股的比例为1.99%。根据测算 ...

Group 1 - The core viewpoint of the news is that Aihuilong's stock price increased by 5.42% to 15.37 CNY per share, with a trading volume of 131 million CNY and a turnover rate of 1.54%, resulting in a total market capitalization of 8.782 billion CNY [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescent immunoassay methods [1] - The company's revenue composition includes: self-produced reagents (non-COVID products) 58.57%, self-produced consumables (non-COVID products) 12.60%, self-produced instruments (non-COVID products) 11.92%, agency reagents 11.02%, agency consumables 3.30%, other (supplementary) 1.89%, agency instruments 0.68%, and software services 0.04% [1] Group 2 - Among Aihuilong's top ten circulating shareholders, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 1.7669 million shares in the third quarter, holding a total of 9.6516 million shares, which represents 1.69% of the circulating shares [2] - The estimated floating profit for Huabao CSI Medical ETF today is approximately 7.6248 million CNY [2] - Huabao CSI Medical ETF was established on May 20, 2019, with a latest scale of 26.404 billion CNY, and has achieved a year-to-date return of 4.86%, ranking 207 out of 5490 in its category [2]

Company Overview - Microelectrophysiology, a company based in Shanghai, specializes in innovative medical devices for electrophysiological intervention and ablation therapy, with a total market capitalization of 11.285 billion yuan as of November 20 [1] - The company was established on August 31, 2010, and went public on August 31, 2022 [1] - Revenue composition includes catheter products (71.77%), other products (20.22%), equipment (7.24%), and leasing services (0.77%) [1] Stock Performance - On November 20, the stock price increased by 5.45%, reaching 23.98 yuan per share, with a trading volume of 63.1665 million yuan and a turnover rate of 2.19% [1] Shareholder Information - Huabao Fund's Huabao Zhongzheng Medical ETF (512170) is among the top ten circulating shareholders, having reduced its holdings by 574,900 shares in the third quarter, now holding 4.0374 million shares, which is 3.23% of the circulating shares [2] - The ETF has a current scale of 26.404 billion yuan and has achieved a year-to-date return of 8.3% [2] Fund Management - The fund manager of Huabao Zhongzheng Medical ETF is Hu Jie, who has a tenure of 13 years and 39 days, managing assets totaling 100.204 billion yuan [3] - The best fund return during Hu Jie's tenure is 183.07%, while the worst return is -98.01% [3]